PharmaSols achieve rapid start-up for complex 1b oncology study

A US-based biopharmaceutical company was looking to run a Complex 1b Oncology study. The study needed to be handled by a CRO that could manage tight timeframes, and it was imperative that it be carried out without costly interruptions. 

The ANZ region is known for their streamlined ethics and regulatory processes, allowing for rapid study start-ups. Having a proven record of flexible and rapid solutions, PharmaSols were chosen as the ideal CRO partner to take on this challenge.  

Being based in New Zealand and Australia, PharmaSols is fortunate to occupy one of the world’s most hospitable locations for conducting clinical research during the COVID-19 pandemic. 

Under all levels of Government restrictions over the last two years, hospitals and healthcare systems have been able to operate as usual in Australia and New Zealand. 

The governments of both countries recognise the importance of clinical studies and have allowed them to run as an essential service, without serious interruption, throughout all Covid-19 lockdowns and alert levels. 


There were several challenges while supporting this study:

  • Requirement for rapid study start-up
  • Need for rapid ethics and regulatory approval in both Australia and New Zealand

Ethics Approvals

PharmaSols received the protocol and submitted the ethics application to the New Zealand Ethics Committee in just one working day. 

After the review meeting, provisional approval was granted in 14 days. Upon receiving the provisional approval, PharmaSols resubmitted the final application within 9 working day, reflecting the amendments required based on the ethics committee’s recommendations. Full approval was granted 20 working days after the second submission.

PharmaSols received ethics approval in New Zealand 55 days from receiving the protocol. The timeframe was even quicker in Australia, with just 36 days from receiving the protocol to full approval. 

Regulatory Approvals

Rapid regulatory timelines were achieved in both Australia and New Zealand. In both countries, PharmaSols made regulatory submissions in 1 day. Full regulatory approval was granted in only 8 days in Australia and 13 days in New Zealand.


The key to PharmaSols’ success in achieving rapid study start-ups is our dedicated in-house start-up team.  This team employs highly efficient processes to capitalise on Australia and New Zealand’s ethics and regulatory timeframes, which are among the fastest in the world. 

Since 2000, our experts have successfully supported global clinical trial teams in Australia and New Zealand and achieved outstanding results for global biotechs, pharma and CROs across hundreds of studies. 

“We have chosen to do many of our clinical trials in New Zealand because the quality of the Investigators, site staff, and clinical research organisations (PSL) is very high, and they have a wonderful ‘can-do’ attitude which is really important for getting clinical trials done on time and on budget.”  - US Biotech Company

PharmaSols are known for our speed, quality, and responsiveness to clients’ needs. To ensure your trial achieves rapid start-up and proceeds without interruption, get in touch with us to see how we can support your success. 

Case Studies

Rapid Study Start-up for Phase 1 Dermatology Study in Australia for a UK Biotech Company

PharmaSols was contracted by a small UK-based biotech company to conduct a Phase 1 dermatology clinical trial in Australia. The sponsor was looking to get the study started within a short period of time to achieve the ‘first patient in’ milestone for their investors.

Read more
Successful Phase 2 Obesity Clinical Trial in the ANZ Region for a US Biotech Company

PharmaSols was contracted by a small US-based biotech company to conduct a Phase 2 obesity clinical trial. The study required the recruitment of 325 eligible participants across 16 sites in Australia and New Zealand.

Read more
Creating Solutions to Deliver Rapid & High-Quality Clinical Trials

Our team have needed to respond quickly to challenges supporting different studies and the experience of our team has enabled us to create rapid solutions for our global sponsors.

Read more
Expedited Timeframes and Exceeded Targets for COVID-19 Diagnostic Trial

PharmaSols were engaged by an organisation looking to run a clinical trial for a COVID-19 diagnostic test. It was imperative that this study be carried out without costly interruptions and needed to be handled by a CRO that could manage tight timeframes.

Read more
Patient Recruitment Targets Exceeded for COVID-19 Vaccine Trial

Due to PharmaSols unique location and history of successful rapid start-ups, we were engaged by a European specialty vaccine company running a COVID-19 vaccine study. This study needed to be conducted without interruptions caused by the virus itself and with a CRO that could handle tight recruitment timeframes.

Read more
Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.

Read more
High Recruitment: Twice as many patients as global CRO

Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more